WCA
ACAD icon

Westover Capital Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Westover Capital Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,592
Closed -$203K – 236
2025
Q4 		$203K Buy
+7,592
New +$181K 0.04% 229

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Westover Capital Advisors's ACAD Position: Q1 2026 in Review

Westover Capital Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q1 2026, closing a stake of 7,592 shares — an estimated $203K sold.

Westover Capital Advisors first reported a position in ACAD in Q4 2025 and held it in 1 quarter. The position peaked at $203K in Q4 2025. 343 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Westover Capital Advisors reported no remaining Acadia Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Westover Capital Advisors sold 7,592 Acadia Pharmaceuticals shares in Q1 2026, an estimated $203K.
  • Westover Capital Advisors first reported a position in Acadia Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Westover Capital Advisors's Acadia Pharmaceuticals position peaked at $203K in Q4 2025.
  • 343 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Westover Capital Advisors's 13F filing for Q1 2026, filed 5 May 2026.